BioSpace News Archive

Nanotechnology has the potential to make immunotherapy/chemotherapy combinations dramatically effective, even against aggressive tumors.

JW Therapeutics, an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced updated 1-year follow-up result of relmacabtagene autoleucel injection for the treatment of relapsed or refractory large B-cell lymphoma at the 24th Annual Meeting of the Chinese Society of Clinical Oncology.

At the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care.

Masimo announced the findings of a study published in the European Journal of Pediatrics in which Dr. Masashi Hotta and colleagues at the Osaka Women’s and Children’s Hospital in Japan found that the Masimo EMMA® Portable Capnograph “may be considered an effective monitoring device” for mechanically ventilated preterm infants.1.

Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd jointly announced the interim clinical data from a Phase 2 trial evaluating taletrectinib, an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive non-small cell lung cancer.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that on September 22 the Brazilian Health Regulatory Agency granted an approval for the phase III clinical trial of proxalutamide to treat hospitalized COVID-19 patients.

Transcenta Holding Limited announces that it received IND clearance on Sept. 22 from NMPA for initiating Phase I clinical trial of TST002, a humanized sclerostin monoclonal antibody for postmenopausal osteoporosis.